Integrating ctDNA, Biomarkers, and Quality of Life Into Treatment Decisions in Advanced RCC

This section transitions into biomarker integration and the role of quality of life in longitudinal care. The panel discusses advances in circulating tumor DNA assays and peripheral blood biomarkers such as KIM-1. Sensitivity of assays has improved significantly, moving from limited variant detection to broader genomic profiling.

Emerging data suggest that combining biomarkers may enhance predictive accuracy for recurrence and progression. In oligometastatic settings, integrating ctDNA with imaging may better guide decisions regarding local therapy versus systemic escalation. Bone metastases are highlighted as a setting where ctDNA may clarify ambiguous radiographic findings.

The conversation then shifts to quality of life considerations. From frontline therapy onward, clinicians must balance efficacy with tolerability. Since many treatments are administered for extended periods, long term toxicity management becomes central to patient care. As patients move into later lines with diminishing response rates, quality of life considerations grow even more prominent.

The panel emphasizes that symptom control from cancer and toxicity management must be weighed simultaneously. Decisions are not binary between efficacy and comfort; rather, they require continuous recalibration.

This segment underscores the evolving movement toward personalized monitoring, integrating molecular tools with clinical judgment while maintaining focus on the patient’s lived experience.